Partner Aaron Tantleff was quoted in an article for SC Magazine, “Survey: 34% of Privacy Pros Expect Their Companies to Certify Under Privacy Shield,” on September 1, 2016. The article discussed a recent survey that underscores the uncertainty around the newly approved EU-U.S. Privacy Shield that found only 34 percent of companies anticipate adopting the framework responsible for secure transatlantic data flow. Tantleff was quoted saying, “This report comes as no surprise. Given the current uncertainty, many are considering a wait-and-see approach or evaluating other means for fear that the Privacy Shield will only last until the one-year grace period afforded by the local data authorities before [it’s challenged]. … Many companies feel that Privacy Shield and the SCCs are just a ticking time bomb.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”